Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?

American Journal of Medicine

Volumn 119, Issue 8, 2006, Pages

  Serebruany, Victor L ^a   Malinin, Alex I ^a   Bhatt, Deepak L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular risk; COX 2 inhibitors; NSAIDs; Platelets

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BLOOD; BLOOD FLOW; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOMETRY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; VASCULAR DISEASE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD31; ANTIGENS, CD36; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; RISK FACTORS;

EID: 33746412348     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.11.007     Document Type: Article

References (34)

1. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
2. FitzGerald G.A. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs. clinical considerations. Am J Cardiol 89 6A (2002) 26D-32D
3. Capone M.L., Tacconelli S., Sciulli M.G., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
4. van Kraaij D.J., Hovestad-Witterland A.H., de Metz M., and Vollaard E.J. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol 53 (2002) 644-647
5. Andrioli G., Lussignoli S., Gaino S., Benoni G., and Bellavite P. Study on paradoxical effects of NSAIDs on platelet activation. Inflammation 21 (1997) 519-530
6. Buerkle M.A., Lehrer S., Sohn H.Y., Conzen P., Pohl U., and Krotz F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 110 (2004) 2053-2059
7. Blaicher A.M., Landsteiner H.T., Zwerina J., et al. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 59 (2004) 1100-1103
8. Van Ryn J., Kink-Eiband M., Kuritsch I., et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 44 (2004) 777-784
9. Andrioli G., Lussignoli S., Ortolani R., et al. Dual effects of diclofenac on human platelet adhesion in vitro. Blood Coagul Fibrinolysis 7 (1996) 153-156
10. Goldenberg N.A., Jacobson L., and Manco-Johnson M.J. Brief communication. duration of platelet dysfunction after a 7-day course of ibuprofen. Ann Intern Med 142 (2005) 506-509
11. Ruggeri Z.M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 31 (1994) 229-239
12. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
13. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann New York Acad Sci 677 (1993) 293-308
14. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. population based nested case-control analysis. BMJ 330 (2005) 1366
15. Johnsen S.P., Larsson H., Tarone R.E., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs. a population-based case-control study. Arch Intern 165 (2005) 978-984
16. Rudic R.D., Brinster D., Cheng Y., et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96 (2005) 1240-1247
17. Jerde T.J., Calamon-Dixon J.L., Bjorling D.E., and Nakada S.Y. Celecoxib inhibits ureteral contractility and prostanoid release. Urology 65 (2005) 185-190
18. Pinheiro R.M., and Calixto J.B. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 51 (2002) 603-610
19. Bulut D., Liaghat S., Hanefeld C., et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 21 (2003) 1663-1667
20. Lin H.P., Kulp S.K., Tseng P.H., et al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3 (2004) 1671-1680
21. Diamond M.P., El-Hammady E., Munkarah A., Bieber E.J., and Saed G. Modulation of the expression of vascular endothelial growth factor in human fibroblasts. Fertil Steril 83 (2005) 405-409
22. Mittra S., Hyvelin J.M., Shan Q., Tang F., and Bourreau J.P. Role of cyclooxygenase in ventricular effects of adrenomedullin. is adrenomedullin a double-edged sword in sepsis?. Am J Physiol Heart Circ Physiol 286 (2004) H1034-H1042
23. De Angelis A., Rinaldi B., Capuano A., Rossi F., and Filippelli A. Indomethacin potentiates acetylcholine-induced vasodilation by increasing free radical production. Br J Pharmacol 142 (2004) 1233-1240
24. Basivireddy J., Jacob M., Pulimood A.B., and Balasubramanian K.A. Indomethacin-induced renal damage. role of oxygen free radicals. Biochem Pharmacol 67 (2004) 587-599
25. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61 (2004) 498-511
26. Yip H.K., Liou C.W., Chang H.W., Lan M.Y., Liu J.S., and Chen M.C. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 20 (2005) 120-128
27. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
28. Chen Z. Randomized, placebo-controlled trial of early clopidogrel in 4600 acute myocardial infarction patients (COMMIT). J Am Coll Cardiol 46 (2005) CS5-CS6
29. Blaicher A.M., Landsteiner H.T., Al-Falaki O., et al. Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. Anesth Analg 98 (2004) 1082-1085
30. Hernandez M.R., Tonda R., Pino M., Serradell M., Arderiu G., and Escolar G. Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. Eur J Clin Invest 34 (2004) 297-302
31. Silverman D.G., Halaszynski T., Sinatra R., Luther M., and Rinder C.S. Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can J Anaesth 50 10 (2004) 1004-1008
32. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
33. Vial J.H., McLeod L.J., and Roberts M.S. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res 21A (1991) 157-160
34. Collet J.P., Montalescot G., Blanchet B., et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110 (2004) 2361-2367